At a glance
- Originator Abbott GmbH & Co. KG
- Class Antihypertensives; Heart failure therapies; Phenylpropionates; Pyrimidines; Small molecules
- Mechanism of Action Endothelin A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Heart failure; Hypertension
Most Recent Events
- 04 Aug 1998 Discontinued - Preclinical for Congestive heart failure in Germany (PO)
- 04 Aug 1998 Discontinued - Preclinical for Hypertension in Germany (PO)
- 24 Mar 1997 Preclinical development for Congestive heart failure in Germany (PO)